Real-time · AI · Cross-signal

Nuvation Bio just made a move. Here's exactly what to do next.

Who to reach, what to say, and why now — on Nuvation Bio, plus every M&A move, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your plan Request a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.

✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.

✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.

✕Clay enriches lists you built — No live signal of its own, no who or when.

✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.

Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline

PUBLIC · NUVBApr 10, 2024•about 2 years ago

Acquiring Company

Nuvation Bio

Acquired Company

AnHeart Therapeutics

New York

New YorkBiotechnologyHealth CareTherapeuticsBiopharmaBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Nuvation Bio Inc., a late-stage global biopharmaceutical company, has successfully completed the acquisition of AnHeart Therapeutics Ltd. This acquisition transforms Nuvation Bio into a well-capitalized, late-stage, global oncology company, expanding its pipeline and positioning it to become a commercial organization.

Company Information

Company

Nuvation Bio

Location

New York, New York, United States

About

Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio’s proprietary portfolio includes mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco. For more information, please visit www.nuvationbio.com.

Related People

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Nuvation Bio's next move

Learn about Strategic plan

M&A Insights

Based on deal data

Integration timeline

70% of M&A integrations take 12-24 months to complete

Tech stack consolidation

83% of merged companies consolidate technology vendors within first year

Post-acquisition investment

Companies increase IT spending by 23% on average after acquisitions

Success factor

M&A deals with strong technology integration plans are 2.5x more likely to succeed